Akero Therapeutics' efruxifermin shows strong potential in MASH, especially compensated cirrhosis. Click here to find out why ...

Braskem is considering expanding its ethylene cracker and polyethylene complex in the Brazilian state of Rio de Janeiro by 220,000 metric tons per year. During a call with analysts, company officials ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss t ...

GSK to buy phase III-ready drug efimosfermin from Boston Pharmaceuticals for as much as $2B British pharmaceutical company GSK (GSK) to acquire Boston Pharmaceuticals’ lead asset, efimosfermin ...

Enter efimosfermin alfa, described as a phase 3-ready, once-monthly injectable fibroblast growth factor 21 (FGF21) analogue with potential across steatotic liver diseases (SLD), including MASH and ...

Bayer BAYRY announced first-quarter 2025 results. Novo NordiskNVO and GSK plcGSK announced licensing deals with smaller biotechs. The FDA granted approval to Merck’s ...

GSK Buys Rights to Phase III-Ready Liver Disease Candidate GSK announced that it is buying rights to clinical-stage biotech Boston Pharmaceuticals' lead pipeline candidate, efimosfermin alfa ...

GSK has announced a $1.2 billion deal to acquire efimosfermin alfa from Boston Pharmaceuticals, writes John George for the ...

GSK Buys Rights to Phase III-Ready Liver Disease Candidate GSK announced that it is buying rights to clinical-stage biotech Boston Pharmaceuticals’ lead pipeline candidate, efimosfermin alfa ...

Wall Street major averages closed significantly higher on Friday, despite softer-than-expected inflation data, and consumer sentiment dropping to the second-lowest on record. Week-to-date, the U.S.

Efimosfermin is a phase III-ready, potential best-in-class, investigational specialty medicine to treat and prevent progression of steatotic liver disease (SLD). Under the agreement, GSK will pay $1.2 ...